Journal of Neuro-Oncology

, Volume 65, Issue 1, pp 3–14 | Cite as

Transferrin Receptor Ligand-Targeted Toxin Conjugate (Tf-CRM107) for Therapy of Malignant Gliomas

  • Michael Weaver
  • Douglas W. Laske


The authors review the preclinical and clinical results of the ligand-targeted toxin conjugate Transferrin-CRM107 (Tf-CRM107), for the treatment of malignant gliomas. Tf-CRM107 is a conjugate protein of diphtheria toxin with a point mutation (CRM107) linked by a thioester bond to human transferrin (Tf). This conjugate exhibits potent cytotoxicity in vitro against mammalian cells expressing the transferrin receptor with activity at picomolar concentrations. Phase I clinical trial results demonstrated that Tf-CRM107, delivered via a high-flow convection method utilizing stereotactically placed catheters, produced tumor response in patients with malignant brain tumors refractory to conventional therapy without severe neurologic or systemic toxicity. The results of a Phase II study are also summarized. Tf-CRM107 treatment results in complete and partial tumor response without severe toxicity in 35% of the evaluable patients. These data warrant a Phase III study as well as continued research in the field of targeted toxin therapy. Future directions of research include optimizing Tf-CRM107 delivery to targeted brain regions, and improving the treatment efficacy by combining with other toxin conjugates targeted to different receptors.

convection enhanced delivery diphtheria toxin glioblastoma multiforme (GBM) malignant brain tumor targeted toxin transferrin transferrin receptor 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fitzgerald DJ, Pastan I: Targeted toxin therapy for the treatment of cancer. J Natl Cancer Inst 81: 1455–1463, 1989Google Scholar
  2. 2.
    Frankel A, Ring D, Bjorn M, et al.: Breast cancer immunotoxins. In: Ceriani RL (ed) Monoclonal Antibodies and Breast Cancer: Proceedings of the International Workshop on Monoclonal Antibodies and Breast Cancer. Martinus Nijhoff Publishing, Boston, 1985Google Scholar
  3. 3.
    Gilliland DG, Steplewski Z, Collier RJ, Mitchell KF, Chang TH, Koprowski H: Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells. Proc Natl Acad Sci USA 77: 4539–4543, 1980Google Scholar
  4. 4.
    Jansen FK, Blyhtman HE, Carriere D, et al.: Immunotoxins: hybrid molecules combining high specificity and potent cytotoxicity. Immunol Rev 62: 185–216, 1982Google Scholar
  5. 5.
    Lashford LS, Davies AG, Richardson RB, et al.: A pilot study of 131I monoclonal antibodies in the therapy of leptomeningeal tumors. Cancer 61: 857–868, 1988Google Scholar
  6. 6.
    Puri RK, Leland P, Kreitman RJ, Pastan I: Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL-4-Pseudomonas exotoxin chimeric protein. Int J Cancer 58(4): 574–581, 1994Google Scholar
  7. 7.
    Trowbridge IS, Domingo DL: Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumor cells. Nature 294: 171–173, 1981Google Scholar
  8. 8.
    Uhr JW: Immunotoxins: Harnessing nature's poisons. J Immunol 133: i–x, 1984Google Scholar
  9. 9.
    Youle RJ, Colombatti M: Immunotoxins: monoclonal antibodies linked to toxin proteins for bone marrow transplantation and cancer therapy. In: Roth JA (ed) Monoclonal Antibodies in Cancer; Advances in Diagnosis and Treatment. Futura Publishing Co., New York, pp. 173–213, 1986Google Scholar
  10. 10.
    Greenfield L, Johnson VG, Youle RJ: Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science 238: 536–539, 1987Google Scholar
  11. 11.
    Johnson VG, Wrobel C, Wilson D, et al.: Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia. J Neurosurg 70: 240–248, 1989Google Scholar
  12. 12.
    Recht L, Torres CO, Smith TW, Raso V, Griffin TW: Transferrin receptor in normal and neoplastic brain tissue: implications for brain tumor immunotherapy. J Neurosurg 72: 941–945, 1990Google Scholar
  13. 13.
    Faulk WP, His BL, Stevens PJ: Transferrin and transferrin receptors in carcinoma of the breast. The Lancet 2: 390–392, 1980Google Scholar
  14. 14.
    Galbraith GMP, Galbraith RM, Faulk WP: Transferrin binding by human lymphoblastoid cell lines and other transformed cells. Cell Immunol 49: 215–222, 1980Google Scholar
  15. 15.
    Gatter KC, Brown G, Trowbridge IS, Woolston RE, Mason DY: Transferrin receptors in human tissues: Their distribution and possible clinical relevance. J Clin Pathol 36: 539–545, 1983Google Scholar
  16. 16.
    Larrick JW, Cresswell P: Modulation of cell surface transferrin receptors by cellular density and state of activation. J Supramil Struct 11: 579–586, 1979Google Scholar
  17. 17.
    Shindelman JE, Ortmeyer AE, Sussman HH: Demonstration of the transferrin receptor in human breast tissue: potential marker for identifying dividing cells. Int J Cancer 27: 329–334, 1981Google Scholar
  18. 18.
    Trowbridge IS, Newman RA, Domingo DL, Sauvage C: Transferrin receptors: structure and function. Biochem Pharmacol 33: 925–932, 1984Google Scholar
  19. 19.
    Hamilton TA, Weiel JE, Adams DO: Expression of the transferrin receptor in murine peritoneal macrophages is modulated in the different stages of activation. J Immunol 132: 2285–2290, 1984Google Scholar
  20. 20.
    Klausner RD, VanRenswoude I, Ashwell G, et al.: Receptormediated endocytosis of transferrin in K562 cells. J Biol Chem 258: 4715–4724, 1983Google Scholar
  21. 21.
    Angelova-Gateva P: Iron transferrin receptors in rat and human cerebrum. Agressologie 21: 27–30, 1980Google Scholar
  22. 22.
    Hill JM, Ruff MR, Weber RJ, Pert CB: Transferrin receptors in rat brain: neuropeptide-like pattern and relationship to iron distribution. Proc Natl Acad Sci USA 82: 4553–4557, 1985Google Scholar
  23. 23.
    Connor JR, Fine RE: The distribution of transferrin immunoreactivity in the rat central nervous system. Brain Res 368: 319–328, 1986Google Scholar
  24. 24.
    Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY: Transferrin receptor on endothelium of brain capillaries. Nature 312: 162–163, 1984Google Scholar
  25. 25.
    Johnson VG, Wilson D, Greenfield L, Youle RJ: The role of diphtheria toxin receptor in cytosol translocation. J Biol Chem 263: 1295–1300, 1988Google Scholar
  26. 26.
    Martell LA, Agrawal A, Ross DA, Muraszko KM: Efficacy of transferring receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors. Cancer Res 53: 1348–1353, 1993Google Scholar
  27. 27.
    Laske DW, Ilercil O, Akbasak A, Youle RJ, Oldfield EH: Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice. J Neurosurg 80: 520–526, 1994Google Scholar
  28. 28.
    Oldfield EH, Laske DW, Youle RJ: Physicians’ IND number BB4570, 1992Google Scholar
  29. 29.
    Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH: Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 91: 2076–2080, 1994Google Scholar
  30. 30.
    Laske DW, Morrison PF, Lieberman DM, Corthesy ME, Reynolds JC, Stewart-Henney PA, Koong S, Cummins A, Paik CH, and Oldfield EH: Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging. J Neurosurg 87: 586–594, 1997Google Scholar
  31. 31.
    Laske DW, Youle RJ, Oldfield EH: Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nature Med 3(12): 1362–1368, 1997Google Scholar
  32. 32.
    Karnofsky DA, Burchenal JH: The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM (ed) Evaluation of Chemotherapy Agents. Columbia University Press, New York, pp. 191–205, 1989Google Scholar
  33. 33.
    Lonser RR, Walbridge S, Garmestani K, Butman JA, Walters HA, Vortmeyer AO, Morrison PF, Brechbiel MW, Oldfield EH: Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg 97: 905–913, Oct. 2002Google Scholar
  34. 34.
    Hagihara N, Walbridge S, Olson A, Oldfield E, Youle R: Vascular protection by chloroquine during brain tumor therapy with Tf-CRM107. Cancer Res 60: 230–234, 2000Google Scholar
  35. 35.
    Grant R, Slattery J, Gregor A, Whittle IR: Recording neurological impairment in clinical trials of glioma. J Neuro-Oncol 19: 37–49, 1994Google Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • Michael Weaver
    • 1
  • Douglas W. Laske
    • 1
  1. 1.Department of NeurosurgeryTemple University School of MedicinePhiladelphiaUSA

Personalised recommendations